Editorial
Nature Biotechnology 26, 475 (2008)
Corrected online: 13 June 2008 | doi:10.1038/nbt0508-475
There is an Erratum (July 2008) associated with this Editorial.
Looking forward, looking back
Abstract
Amgen's retrospective sortie into personalized Vectibix treatment poses some difficult questions for regulators concerning the oversight of companion diagnostics.
* In the version of this article initially published, in paragraph 4, the generic name and ligand given for Avastin are incorrect. The correct generic name is bevacizumab and its target is VEGF (vascular endothelial growth factor). The error has been corrected in the HTML and PDF versions of the article.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Chutes and Ladders on the Critical Path:Comparative Effectiveness, Product Value, and the Use of Biomarkers in Drug DevelopmentClinical Pharmacology & Therapeutics News and Views
Medical Oncology IROX as second-line therapy for metastatic colorectal cancerNature Reviews Clinical Oncology News and Views (01 May 2009)
